Collaborative Pilot Programs

Pilot projects that promote pre-clinical/clinical concepts and team science, support the planning of multi-investigator grants and foster collaboration across Columbia through transdisciplinary cancer research projects. Participation by individuals from underrepresented groups is strongly encouraged in all funding mechanisms.

HICCC Inter/Intra-Programmatic Pilot Program (IPPP)

Focus: Assembling collaborative teams to gather preliminary data to address unsolved questions across the full spectrum of cancer research.

Who Should Apply: HICCC members – should be from at least two different HICCC Research Programs. HICCC senior leadership not eligible.

Award Amount: $80,000 for 1 year

Applications typically open in April. Up to 2 awards expected per cycle.

Past Awardees: 

2023 Awardees:

  • Xuebing Wu, PhD, Jianwen Que, MD, PhD, Targeting MYC-driven cancer with CRISPR/Cas13 collateral activity
  • Lance Kam, Nicole Lamanna, MD, Jia Guo, Accelerating immunotherapy through a rapid test of T cell health

2022 Awardees:

  • Larisa Geskin, MD, Nick Tatonetti, PhD, Itsik Pe'er, Artificial Intelligence and Machine Learning to Examine the Clinical-Genomic Correlation in Cutaneous T-Cell Lymphoma
  • Swarnali Acharyya, PhD, Chao Lu, PhD, Catherine Shu, MDIdentifying epigenetic drivers of brain relapse in lung cancer: mechanistic and translational studies

2021 Awardees:

  • Akiva Mintz, MD, PhD, Tal Danino, PhD, Nicholas Arpaia, PhD, Elisa KonofagouMaximizing anti-GBM activity of engineered therapeutic probiotics

2020 Awardees:

  • Ran Reshef, MD, MSc, Elham Azizi; Identification of a targetable macrophage maturation defect in human intestinal graft-versus-host disease by using advanced single-cell technologies and machine learning tools
  • Peter Canoll, MD, PhD, Peter Sims, PhD, Brent Stockwell, PhD, Jeffrey Bruce, MDTargeting Glioblastoma with Ferroptosis

HICCC Multi-Principal Investigator (PI) Planning Grant

Focus: Support for the submission of multi-component biomedical research grants and large multi-PI research grants.

Who Should Apply: Columbia University faculty. HICCC senior leadership is eligible.

Award Amount: $80,000 for 1 year

Applications typically open in March. Up to 2 awards expected per year.

Past Awardees:

2024 Awardees:

  • Tannishtha Reya, PhD, Identifying New Dependencies of Therapy Resistant Pancreatic Cancer Cells
    • ​​​​Co-awardees: Kenneth Olive, PhD & Christine Chio, PhD
  • Sandra Ryeom, PhD, Gastric Cancer Across the Continuum; from Early Detection to Metastatic Progression
    • Co-awardeesChin Hur, MD, MPH, Akiva Mintz, MD, Ryan Moy, MD PhD, Timothy Wang, MD, Zhigou Zhang, PhD

2023 Awardees:

  • Michael Shen, PhD, Cory Abate-Shen, PhD, Modeling bladder cancer pathogenesis and tumor evolution

2022 Awardees:

  • Hiroshi Nakagawa, MD, PhD, Understanding and targeting epigenetic and metabolic alternations in HNSCC pathobiology 
    • Co-Principal Investigator: Chao Lu, PhD
    • Co-Investigators: J. Alan Diehl, PhD, Quintin Pan, PhD, Theodoros Teknos, MD.

  • Jeffrey Bruce, MD, Convection-enhanced delivery for brain tumors
    • Co-Principal Investigator: Peter Canoll, MD, PhD 
    • Co-Investigators: Andrea Califano, MD, Andrew Lassman, MD, Raul Rabadan, PhD, Peter Sims, PhD

2021 Awardees:

  • Michael Shen, PhD, Cory Abate-Shen, PhDInvestigating cell-intrinsic and extrinsic interactions in prostate cancer at the single-cell level
  • Stavroula Kousteni, PhD, Emmanuel Passegue, PhD, Adolfo Ferrando, MD, Epigenetic remodeling, emergency myelopoiesis and stromal cell signaling-induced stem cell reprograming  in AML transformation

2020 Awardees:

  • Angela Yoon, DDS, MPH, MAMSc, Elizabeth Philipone, DMD , Hiroshi Nakagawa, MD, PhD, Richard Carvajal, MD, Gloria Su, PhD, Fatemeh Momen-Heravi, DDS, PhD, MPH, MS, Collaborative Projects in Oral Dysplasia and Carcinoma
  • Robert Schwabe, MD, Ira Tabas, MD, PhD, Utpal Pajvani, MD, PhDUnderstanding and targeting cell-cell crosstalk in NASH-associated liver fibrosis and liver cancer
  • Stephen Goff, PhD, Songtao Jia, PhD, Zhiguo Zhang, PhD, Chao Lu, PhD, Jennifer Amengual, MDEpigenetic Regulation of Endogenous Retroviral DNAs and Consequences for Tumor Immunotherapy

HICCC Velocity Cancer Pilot Awards

Focus: Bi-directional translational cancer research that drives basic, translational, clinical, community, and population science research, generating novel hypothesis-testing research questions.

Who Should Apply: Columbia University faculty engaged in new or established cancer or cancer-relevant research are eligible. Special consideration for disease teams or researchers who participated in the Velocity Ride. Preference given to early career investigators. (HICCC senior leadership is not eligible.)

Award Amount: $100,000 for 1 year.

Applications typically open in February. Up to 4 awards expected per cycle.

Past Awardees:

2023 Awardees:

  • Elisa E. Konofagou, PhDTumor Mechanical Properties For Predicting Breast Cancer Treatment Response
    • Co-Investigators: Julia E. McGuinness, MD, Richard S. Ha, MD, Md Murad Hossain, PhD
  • Jack Grinband, PhD, Using time domain diffuse optical tomography (TD-DOT) to measure BOLD asynchrony in glioblastoma​​​
    • Co-Investigators: Ken Shepard, PhD, Peter D. Canoll, MD, PhD, Jeffrey N. Bruce, MD, Fabio M. Iwamoto, MD
  • Edmond M Chan, MD ​​, Potentiating antibody-based therapies in gastro/gastroesophageal cancers
    • Co-Investigators: Jellert Gaublomme, PhD
  • Juan Manuel Schvartzman, MD, PhD, ​​​​​Levering metabolism-dependent synthetic lethalities between epigenetics and replication stress in cancer
  • Jeanine Genkinger, PhDSupportive TReatment to Improve Vitality and Energy (STRIVE) Cohort

    • Co-Investigators: Silvia Martins, MD, PhD, Jason D. Wright, MD, Melissa Accordino, MD, Katherine M. Keyes, PhD, Lauren Houghton, PhD

2022 Awardees: 

  • Lauren Houghton, PhD, “NEW PARADIGM Breast Cancer in Black Women”
    • Co-Investigator: Jasmine A. McDonald, PhD.
  • Chin Hur, MD, ​​​​​“Real World Integration of Liquid Biopsy Cancer Tests into Gastrointestinal Cancer Early Detection”

    • ​​​​Co-Investigator: Fay Kastrinos

  • Markus D. Siegelin, MD, ​​​​​​“Targeting Metabolic Liabilities Induced by AURKA Inhibition in Glioblastoma”

    • Co-Investigator: Guoan Zhang, PhD

  • Neil Vasan, MD, PhD“Large scale functional examination of PIK3CA variants and PI3K inhibitor sensitivity in breast cancer”
    ​​​​​​

2021 Awardees:

  • Iok I. Christine Chio, PhD, “A Chemical Proteomic Approach to Overcome Immune Evasion in Pancreatic Cancer”

    • Co-investigator: Marko Jovanovic, PhD

  • Eileen Connolly, MD, “Checkpoint Inhibition and High-dose Radiation”

    • Co-investigator: Darrell Yamashiro, MD

  • John C. Markowitz, MD“Randomized Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Depression In Patients with Non-Metastatic Breast Cancer”

    • Co-investigators: David Hellerstein, MD; Dawn Hershman, MD

  • Laura Pasqualucci, MD, ​​​​​​“Hypermutated super-enhancers identify novel therapeutic targets in diffuse large B cell lymphoma”

    • Co-investigators: Riccardo Dalla-Favera, MD; Alberto Ciccia, PhD

  • Hee Won Yang, PhD“Deciphering mechanisms of CDK4/6-inhibitor resistance to determine new breast cancer therapeutic opportunities”

    • Co-investigators: Gary Schwartz, MD; Hanina Hibshoosh, MD, PhD; and Minah Kim, PhD

2020 Awardees:

  • Benjamin Izar, MD, PhD, “Dissecting Melanoma Brain Metastases by Molecular, Spatial, and Functional Single-Cell Profiling”
  • Minah Kim, PhD, “Targeting Vascular Abnormalities to Overcome Immune Checkpoint Inhibitor Resistance in Metastatic Melanoma”
  • Chao Lu, PhD, “Expanding Epigenetic Therapies for Diffuse Large B-cell Lymphoma”
  • Parisa Tehranifar, DrPH, “Reducing Overscreening and Supporting Informed Mammography Screening Decisions in Older Women”

HICCC Edward P. Evans Center for Myelodysplastic Syndromes (MDS) Pilot Award

Focus: Advance understanding in the early stages of MDS and implement innovative approaches in disease management/prevention.

Who Should Apply: Members of the Edward P. Evans Center for MDS, Columbia faculty engaged in MDS research or related areas of expertise.

Award Amount: $100,000 for 1 year

Applications typically open in March. Up to 2 awards expected per cycle.

Past Awardees:

2023 Awardees:

  • Sara Zaccara, PhD, “Predicting AML by Means of m6A and YTHDF Proteins Activity” 
  • Aaron Viny, MD, “Nucleolar Dysfunction as a Therapeutic Liability in Cohesin Mutant MDS” 
    • Co-Investigator: Hans Scnoek Willem, MD, PhD

2022 Awardees:

  • Pawel Muranski, MD and Amer Assal, MD , “Multi-Epitope Specific Cytotoxic CD4+ T Cells for Adoptive Immunotherapy of Myelodysplastic Syndrome” 
    • Co-investigators: Azra Raza, MD; Markus Y. Mapara, MD; Mithil K. Soni, PhD
  • Raul Rabadan, PhD, ​​​​​​“Systematic Protein Structure Characterization of Mis-spliced Transcripts in Myelodysplastic Syndromes” ​​​​​​
    •  Co-Investigator: James Manley, PhD

HICCC and ICAP Global Cancer Research Pilot Program

Focus: Global cancer education, treatment and prevention gaps. Offered in partnership with ICAP, a leader in global public health based at Columbia to gather preliminary data for major grants from the NIH and other funding organizations.

Who Should Apply: Columbia University faculty or research scientists. Those involved in cancer related interdisciplinary research are encouraged to apply.

Award amount: $30,000 for 1 year

Applications typically accepted in August. Up to 2 awards expected per cycle.

Past Awardees:

2023 Awardees:

  • Jeanine Genkinger, "Turning data into cancer prevention: Assessing diet, metals, mycotoxin, and Inflammation in the Indian Study of Heath for Adults (ISHA)"
    • Co-investigators: Hui-Chen Wu; Kathrin Schilling; Sharayu Mhatre; Rajesh Dikshit 

2022 Awardees: 

  • Yoanna Pumpalova, MD, “Development of a clinical prediction model to improve colorectal cancer outcomes in South Africa” 
  • Adana Llanos Wilson, PhD, MPH“Personal care and hair product use among women in Kenya: Assessment of knowledge, attitudes, and perceptions of use in the context of breast cancer risk” 
  • Kara Cicero, MD, “Prevalence and risk factors of monoclonal gammopathy of undetermined significance in a Black Sub-Saharan African population” 

2021 Awardees: 

  • Grace Hillyer, EdD, “Developing a tobacco control program delivered by community health workers in Johannesburg, South Africa” 
  • Hui-Chen Wu, DrPH, Jasmine A. McDonald, PhD,“Biological age acceleration, reproductive history, and early onset breast cancer risk in Ghanaian Women” 

HICCC-School of Engineering and Applied Sciences (SEAS) Joint Pilot Grants

Focus: Joint seed funding to support new collaborations at the intersection of cancer and engineering.

Who Should Apply: SEAS and HICCC Mid-career and senior faculty/researchers. HICCC senior leadership is eligible.

Award Amount: $80,000 for 1 year

Applications typically awarded in January. Up to 2 awards expected per year.

Past Awardees:

2022 Awardees:

  • Brent Stockwell, PhD; Elham Azizi, PhD, "Identifying 3D tumor metabolic neighborhoods using mass spectrometry imaging"
  • Kenneth Olive, PhD; Christoph Juchem, PhD, "Measuring ferroptosis in vivo using magnetic resonance spectroscopy"

2021 Awardees:

  • Lance Kam, PhD; Benjamin Izar, MD,"T cell Adoptive Immunotherapy Through 3D Biomaterials and Mechanobiology"
    • Co-investigators: Helen Lu, PhD, Ran Reshef, MD, MSc

2020 Awardees: 

  • Peter Sims, PhD; Sam Sia, PhD, "Microfluidic platform for automated multiplexed drug testing on intact biopsy samples"
  • Adolfo Ferrando, MD, PhD; Gordana Vunjak-Novakovic, PhD, "Patient-specific leukemia-bone marrow organoid culture and therapeutic platform"​​​​​​

HICCC-Faculty of Arts and Sciences (FAS) Joint Seed Cancer Research Pilot Grants

Focus: Supports interdisciplinary research at the intersection of biological and cancer research to provide new insight into fundamental mechanisms relevant to cancer. The program supports new collaborations that will lead to faculty relationships across Columbia disciplines.

Who Should Apply: Faculty from both FAS and HICCC. Asst prof level or higher appointments. HICCC senior leadership is eligible to apply.

Award Amount: $100,000 for 1 year.

Applications typically open in July. 1 award expected per cycle.

Past Awardees:

2023 Awardees:

  • Yvon Woappi, PhD ; Ishmail Abdus-Saboor, PhD, NEED TITLE​​​​​​

2022 Awardees:

  • Teresa Palomero, PhD; Rafael Yuste, "Optically-released JAK inhibitors for cutaneous lymphoid malignancies"

2021 Awardees:

  • Angela Christiano, PhD; Lewis Brown, "Detection of Tumor Neoantigens after Induction of PTC Readthrough and Inhibition of Nonsense Mediated mRNA Decay using Immunopeptidome Analysis"
  • Yiping Han, PhD , Ann McDermott, PhD, "Investigation of amyloid-like FadA adhesin by solid phase NMR"

2020 Awardees:

  • Jellert Gaublomme, PhD; Raul Rabadan, PhD, "Single-cell and Spatial Transcriptomic Analysis of Intercellular Networks  in the Tumor Microenvironment in Glioblastoma"
  • Laura Kaufman, PhD, Carol Prives, PhD, "Identification of p53-dependent pro-metastatic metabolic pathways in 3D invasive cancer cells"